<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119290">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01835470</url>
  </required_header>
  <id_info>
    <org_study_id>IM101-365</org_study_id>
    <nct_id>NCT01835470</nct_id>
  </id_info>
  <brief_title>Efficacy, Safety, Pharmacokinetics and Immunogenicity Study of Abatacept Administered Intravenously to Treat Active Polyarticular-course Juvenile Idiopathic Arthritis in Japan</brief_title>
  <official_title>A Phase III, Multicenter, Open-Label Study to Assess Efficacy, Safety, Pharmacokinetics and Immunogenicity of Abatacept Administered Intravenously in Japanese Children and Adolescents With Active Juvenile Idiopathic Arthritis Who Have a History of an Inadequate Response or Intolerance to Methotrexate or Biologics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ono Pharmaceutical Co. Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>Japan: Institutional Review Board</authority>
    <authority>Japan: Pharmaceuticals and Medical Devices Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy of Abatacept after intravenous
      administration in Japanese children and adolescents with active juvenile idiopathic
      arthritis who have a history of an inadequate response or intolerance to Methotrexate or
      biologics
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>American College of Rheumatology (ACR) Pediatric 30 response rate</measure>
    <time_frame>Week 16 (Day 113)</time_frame>
    <safety_issue>No</safety_issue>
    <description>ACR pediatric 30 response is defined as '≥30% improvement' and '≥3 of the 6 Juvenile Idiopathic Arthritis (JIA) core set'
And ≥30% worsening in not more than 1 of the 6 JIA core set variables</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ACR pediatric 50 and 70 response rates</measure>
    <time_frame>Week 16 (Day 113)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disability index of the Childhood Health Assessment Questionnaire (CHAQ)</measure>
    <time_frame>Week 16 (Day 113)</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety summarized by proportion of subjects with Adverse Events (AEs), deaths, Serious Adverse Events (SAEs), and AEs of special interest</measure>
    <time_frame>Up to Week 16 (Day 113) - Short term (ST) period</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of Abatacept</measure>
    <time_frame>9 time points up to Week 16 (Day 113) - ST period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetics summary statistics (geometric mean and coefficient of variation) will be presented for Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed concentration (Ctrough) of Abatacept</measure>
    <time_frame>9 time points up to Week 16 (Day 113) - ST period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pharmacokinetics summary statistics (geometric mean and coefficient of variation) will be presented for Ctrough</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity positive rates</measure>
    <time_frame>Up to Week 16 (Day 113) - ST period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Assessment of positive response is determined based on an assay cutpoint value. For the electrochemiluminescence (ECL) assay, for all summaries and listings unless specified otherwise, a positive immunogenicity response for 'Cytotoxic T-lymphocyte antigen (CTLA4) and possibly Immunoglobulin (Ig)', 'Ig and/or Junction Region', respectively, is defined as:
A missing baseline immunogenicity measurement and a positive analytical laboratory reported immunogenicity response post-baseline
A negative baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline
A positive baseline immunogenicity response and a positive analytical laboratory reported immunogenicity response post-baseline that has a titer value strictly greater than the baseline titer value</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Juvenile Idiopathic Arthritis</condition>
  <arm_group>
    <arm_group_label>Abatacept</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Abatacept 10 mg/kg (for body weight less than 75 kg), 750 mg (for body weight between 75 and 100 kg), and 1g (for body weight above 100kg) intravenous infusion on Week 0 (Day 1), Week 2 (Day 15), Week 4 (Day 29) and every 4 weeks (28 days) thereafter up to the end of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abatacept</intervention_name>
    <arm_group_label>Abatacept</arm_group_label>
    <other_name>BMS-188667</other_name>
    <other_name>ONO-4164</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects who have a history of an inadequate therapeutic response or intolerance in
             the opinion of the examining physician to at least one biologics or  Methotrexate
             (MTX).

          -  Diagnosis of Juvenile Idiopathic Arthritis (JIA) by International League of
             Associations for Rheumatology (ILAR) criteria as oligoarticular, polyarticular
             Rheumatoid Factor (RF+), polyarticular (RF-), or systemic with a
             polyarticular-course.

          -  Men and women, ages 4 to 17 years, inclusive at enrollment.

          -  Subjects must have a history of at least 5 joints with active disease and must have
             currently active articular disease as defined by:

               1. ≥2 active joints (e.g. presence of swelling, or if no swelling is present,
                  limitation of motion (LOM) accompanied by pain, tenderness, or both) at
                  screening and at Week 0 (Day 1).

               2. ≥2 joints with LOM at screening and at Week 0 (Day 1).

        Exclusion Criteria:

          -  Systemic onset JIA with any of the following manifestations within the last 6 months
             prior to enrollment: intermittent fever due to JIA, rheumatoid rash,
             hepatosplenomegaly, pleuritis, pericarditis, or macrophage activation syndrome.

          -  Presence of any other rheumatic disease or major chronic
             infectious/inflammatory/immunologic disease (e.g. inflammatory bowel disease,
             psoriatic arthritis, spondyloarthropathy, hypogammaglobulinemia, or systemic lupus
             erythematosus, etc.)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information, please email:</last_name>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT# and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Oobu-shi</city>
        <state>Aichi</state>
        <zip>4748710</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>0048618</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kobe-shi</city>
        <state>Hyogo</state>
        <zip>6540081</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kagoshima-shi</city>
        <state>Kagoshima</state>
        <zip>8900075</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa</state>
        <zip>2360004</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0001</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>9893126</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0003</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Niigata-shi</city>
        <state>Niigata</state>
        <zip>9518520</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Takatsuki-shi</city>
        <state>Osaka</state>
        <zip>5698686</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bunkyo-ku</city>
        <state>Tokyo</state>
        <zip>1138603</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0007</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>1620054</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://ctr.bms.com/ctd/start.do</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>May 27, 2014</lastchanged_date>
  <firstreceived_date>April 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Juvenile Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Abatacept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
